In lung cancer, the upregulation of TOPK was reported to promote chemical‐resistance towards EGFR tyrosine kinase inhibitors,16 and facilitate hypoxia‐induced epithelial‐mesenchymal transition and the invasion of NSCLC cells.17 This evidence concerns the gene PBK and non-small cell lung carcinoma.